{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3"},{"groupId":"OG001","value":"97.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"460"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"Percentage of participants with at least one adverse event.","groups":[{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Atezolizumab Plus Nab-Paclitaxel"},{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo Plus Nab-Paclitaxel"}],"paramType":"NUMBER","populationDescription":"The safety-evaluable population is defined as participants who received any amount of any study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to to the data cutoff date: 31 August 2021 (up to approximately 74 months)","title":"Percentage of Participants With at Least One Adverse Event","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}